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Running and Mortality: Is
More Actually Worse?
To the Editor: In follow-up to our
recent state-of-the-art review on running
published in theNovember2015 issueof
Mayo Clinic Proceedings,1 we have addi-
tional data regarding the relationship of
high-dose running with prognosis.
Clearly, observational studies have re-
cently reported that leisure-time running
provides mortality benefits. However,
the dose-response relationship between
running and mortality has been increas-
ingly debated, specifically whether more
running is better or worse.
The Copenhagen City Heart Study
(CCHS) indicated a reverse J-shaped as-
sociation between weekly jogging time
or frequency and all-cause mortality,
suggesting loss of mortality benefits
with higher doses of jogging at 2.5
hours or more per week or 4 times or
more per week in a relatively healthy
cohort (N¼5048).2 Similarly, our
recent analysis of running and cause-
specific mortality suggested a reverse
J-shaped association, specifically on cor-
onary heart disease mortality, unlike
other causes of death.3 Data from the
National Runners’ and Walkers’ Health
Studies (NRWHS) of 2377 heart attack
survivors also indicated a reverse
J-shaped association of running or
walking with all-cause and cardio-
vascular disease (CVD) mortality,
with loss of benefit at high exercise
doses.4 Both the CCHS and NRWHS
have limitations. The CCHS had rela-
tively small numbers of deaths and
used sedentary nonjoggersdie, without
including active nonjoggers who are
active in other types of physical activity
except joggingdas the reference group
in their analysis. This factor, in turn,
may contribute to greater mortality
benefits in joggers. The NRWHS had
no nonrunning inactive control group
but used inadequate exercisers (<1.07
metabolic equivalent task [MET]eh/d)
as the reference group in their analyses.
In our large study of running and
mortality from the Aerobics Center Lon-
gitudinal Study (ACLS) in 55,137 par-
ticipants (13,016 runners [24%] and
3413 deaths [6%]),5 we found different
results. Specifically, we found signifi-
cantly lower all-cause and CVD mortal-
ity risks even in the highest quintiles of
running doses compared with no
running, although mortality benefits
trended slightly less at the highest
quintiles.
Current Study. In the current study,
the large sample size from the ACLS
allowed us to further investigate
whether “more is better or worse”
regarding running andmortality. Partic-
ipants in the highest quintiles of
running doses were additionally classi-
fied into 3 tertiles of running time, dis-
tance, frequency, and total amount.
Detailed information on the study
design and the assessment of running
has been described previously.5 We
found that the mortality benefits were
not significant in the highest tertiles of
running compared with no running
(P.05) (Figure), similar to the findings
of the other major running studies
mentioned previously. However,
although there was apparent loss of
benefit in the highest-dose runners,
partly due to the smaller numbers and
wider confidence intervals (CIs), there
was no increase in mortality but rather a
declining trend in benefit in all-cause
and CVD mortality, even at the high-
est dose compared with nonrunners.
Therefore, there may be no remarkable
increase in mortality risk compared
with nonrunners no matter how much
one runs, although there also may be no
mortality benefits in excessive running.
Another interesting and important
question focuses on the effects of high
doses of running compared with low
doses of running. (Low-dose running
generally provided the most favorable
mortality benefits in all 3 of the previ-
ously discussed studies.) In the CCHS,
considering both duration and speed
of jogging, the authors found that the
moderate and strenuous joggers who
jogged more or at a faster speed (4
times/wk or 2.5 h/wk at <7 mph
or any running at7mph) (to convert
to kph, multiply by 1.6) had 3-fold
and 9-fold significantly increased risks
of mortality, respectively, compared
with light joggers, who jogged less at
a slower speed (<2.5 h/wk at 7
mph). However, their analyses in-
cluded very small numbers of deaths
in the light (n¼7), moderate (n¼8),
and strenuous (n¼2) joggers. The
NRWHS also reported similar results
using total amount of running/
walking based on both duration and
speed. Cardiovascular disease mortal-
ity increased 2-fold in the group with
the highest amount of running/
walking (7.2 MET-h/d) compared
with the group with the lower amount
(3.6-7.2 MET-h/d), with a hazard ratio
(HR) (95% CI) of 1.97 (1.00-3.67)
(P¼.05), based on 13 deaths in the
highest running/walking group.
We conducted similar analyses and
found different results, indicating no
significant differences in all-cause mor-
tality (HR, 1.27; 95% CI, 0.89-1.81;
P¼.19) and CVD mortality (HR, 1.66;
95% CI, 0.87-3.16; P¼.12) in the high-
est (2944 MET-min/wk, which is
equal to 7 MET-h/d) compared with
the lowest (<506 MET-min/wk, which
is equal to <1.2 MET-h/d) amounts of
running, although HRs were greater in
those at the highest exercise levels.
Similar results were observed in both
men and women, with HRs (95% CIs)
of 1.21 (0.84-1.75) and 1.84 (0.95-
3.54) for all-cause and CVD mortality,
respectively, in men and 3.07 (0.79-
11.91) for all-cause mortality in women
(there were no CVD deaths in women
running the highest running amount).
Similar results were also found in young
and old individuals (<50 vs50 years)
with HRs (95%CIs) of 1.57 (0.98-2.51)
and 2.01 (0.81-5.02) for all-cause and
CVD mortality, respectively, in young
individuals and 0.93 (0.52-1.64) and
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1.19 (0.47-3.02) for all-cause and CVD
mortality, respectively, in old individ-
uals. Moreover, slow and fast runners
(<6.7 vs 6.7 mph, using median
speed) had similar results, with HRs
(95% CIs) of 1.54 (0.79-2.99) and
1.24 (0.37-4.18) for all-cause and
CVD mortality, respectively, in slow
runners and 1.41 (0.87-2.28) and 2.47
(0.98-6.21) for all-cause and CVD
mortality, respectively, in fast runners.
Therefore, our findings from a consider-
ably larger number of runners and
deaths suggest again that there may be
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FIGURE. Hazard ratios of all-cause and cardiovascular disease (CVD)mortality by weekly running time, distance, frequency, and total amount.
Participants were classified into 8 groups: nonrunners and 5 quintiles of each running dose (Q1 to Q5) with the last quintile (Q5) additionally
categorized into 3 tertiles (Q5-T1,Q5-T2, andQ5-T3) using largermarkers (7 groups for running frequency because of limited numbers in7
times/wk). All hazard ratios were adjusted for baseline age (years), sex, examination year, smoking status (never, former, or current), alcohol
consumption (heavy drinker or not), other physical activities except running (0, 1-499, or500 metabolic equivalent task minutes per week
[MET-min/wk]), and parental CVD (yes or no). The number of participants (number of all-cause deaths)were 42,121 (2857), 2710 (110), 2584
(116), 2505 (103), 2647 (112), 850 (33), 822 (30), and898 (52) in the corresponding8 running timegroups fromnonrunners toQ5-T3; 42,121
(2857), 2626 (105), 2473 (120), 2961 (123), 2218 (92), 885 (36), 1027 (40), and 826 (40) in running distance; 42,121 (2857), 2757 (62), 3076
(105), 2817 (131), 2500 (143), 1215 (66), and 651 (49) in running frequency; and 42,121 (2857), 2609 (109), 2598 (122), 2558 (116), 2626
(105), 863 (31), 886 (30), and 876 (43) in total running amount. The number of participants (number of CVD deaths) were 40,319 (1055),
2628 (28), 2501 (33), 2435 (33), 2567 (32), 827 (10), 801 (9), and 863 (17) in the corresponding 8 running time groups from nonrunners to
Q5-T3; 40,319 (1055), 2550 (29), 2386 (33), 2874 (36), 2156 (30), 858 (9), 1001 (14), and 797 (11) in running distance; 40,319 (1055), 2714
(19), 2993 (22), 2725 (39), 2396 (39), 1174 (25), and 620 (18) in running frequency; and 40,319 (1055), 2531 (31), 2508 (32), 2477 (35), 2553
(32), 842 (10), 864 (8), and 847 (14) in total running amount. The bars indicate 95% CIs, and hazard ratios appear next to the bars.
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risk associated with a higher amount
of running, even compared with a
lower amount of running (which pro-
vided the maximal mortality bene-
fits), although it is still possible that
more may be worse. Therefore,
further exploration is clearly war-
ranted to investigate whether there
is an optimum upper limit of running
beyond which additional running
produces adverse health effects.
Conclusion. People run not only to
improve health but also for competi-
tion, fitness, weight management, stress
relief, socialization, or fun. As a popular
and convenient leisure-time physical
activity, running provides numerous
additional health benefits, including
lower risks of obesity, hypertension,
dyslipidemia, type 2 diabetes, stroke,
osteoarthritis, and certain cancers.1
Many studies, including ours, support
that a small amount of running, even
below the current minimum guidelines
(<75 min/wk), can substantially reduce
mortality risk and extend life. Despite
the study limitations, our results clearly
suggest that regarding running and
mortality, “more is not better,” and our
highest runners (still only in the low to
mid 30 miles per week range) had a
trend of loss of benefit; nevertheless,
these highest runners still had trends of
lower mortality than did nonrunners
and only a nonsignificant trend of
higher mortality than did the lower-
dose runners (P.05). Therefore, until
we have more compelling evidence on
running doses andmortality, we should
emphasize that “even a little is great”
rather than debating whether “more is
better or worse” from a public health
perspective.
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To the Editor: I appreciated the
insightful data presented by Shana-
felt et al1 in their article in the
December 2015 issue of Mayo Clinic
Proceedings, and I share the con-
cerns about burnout rates among
physicians in the United States.
Although burnout is undoubtedly a
multifactorial issue, one wonders
about the role of recent federal
mandates.
Speaking as an endocrinologist
who is engaged in the care of patients
daily, a major source of stress stems
from the implementation of electronic
medical records (EMRs), the pressure
from the federally mandated Mean-
ingful Use programs that provide in-
centives to physicians who meet the
implementation criteria, and the
financial penalties imposed on those
who do not.2 Although the goals
may be beneficentdie, to track and
share clinical conditions and to use
the information to engage patients
and their familiesdthe reality is that
the currently employed EMR often re-
sults in needlessly complicated tasks
for the physician with questionable
clinical benefit to the patient. In
addition, clinical notes have become
much lengthier because of required
information and verbiage, without
containing more relevant data that
have utility for the reader. Physician
EMR training requires hours to
complete, while familiarization
with the system requires months
of use. In addition, each upgrade
of existing systems to meet the
next stage of Meaningful Use is
costly. Indeed, some senior physi-
cians in our health care practice
group have opted to retire early
rather than be burdened by the
“forced” complicated digitization of
patient records.
Another issue relevant to physi-
cians concerns obtaining supplies for
Medicare patients. No longer is a pre-
scription for glucometer strips for an
insulin-dependent diabetic patient
sufficient; health care professionals
now need to justify why a patient
needs to test more than 3 times a
day and must periodically complete
paperwork attesting to this need.
Clinics are asked by some suppliers
to keep a copy of patient glucose
logs over a 6-month period. For pa-
tients requiring diabetic shoes, Medi-
care does not consider a podiatrist’s
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